This trial is unknown status.

Condition amphetamine-related disorders
Treatment selegiline
Phase phase 1
Sponsor National Institute on Drug Abuse (NIDA)
Start date September 2001
End date October 2002
Trial size 16 participants
Trial identifier NCT00033072, NCT00024882, NIDA-CTO-0004-1


The purpose of this study is to assess the potential interactions between intravenous methamphetamine and oral selegiline.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Masking single blind
Primary purpose treatment

Primary Outcomes

safety of selegiline
time frame:
pharmacokinetic assessment
time frame:

Eligibility Criteria

Male or female participants from 18 years up to 45 years old.

Inclusion Criteria: - Volunteers who meet DSM-4 criteria for methamphetamine abuse or dependence; non-treatment seeking individuals - Be able to verbalize understanding of consent form; provide written informed consent Exclusion Criteria: - Please contact site for more information

Additional Information

Official title Assessment of Potential Interactions Between Intravenous Methamphetamine and Oral Selegiline
Principal investigator Thomas Newton, M.D.
Description To determine the safety of the selegiline concurrent with d-methamphetamine challenges of 15mg & 30mg i.v. with the focus being on cardiovascular responses (HR,BP) to the i.v. methamphetamine challenges. This is a randomized, single-blind, placebo-controlled, two-arm study design to evaluate the safety of selegiline treatment, compared to placebo treatment, concurrent with i.v. methamphetamine challenges.
Trial information was received from ClinicalTrials.gov and was last updated in January 2017.
Information provided to ClinicalTrials.gov by National Institute on Drug Abuse (NIDA).